The beginning of cell and gene therapy biopharma Vector BioPharma was announced by San Francisco-based medical investment company Versant Ventures. Using a unique platform based on research conducted by the University of Zurich, Vector BioPharma will create next-generation pharmaceuticals. Using unmatched precision and versatility, the company claims that its platform "delivers the appropriate gene to the right spot at the right time #CellTherapyMarketSize #GeneEditingMarketSize